Skip to content

Ketamine for depression: all studies

Page 19 of 154: studies 181 to 190 of 1,534, newest first. Back to the ketamine for depression overview

Research

From synapse to strategy: a bibliometric map of ionotropic glutamate receptors in depression.

Naunyn-Schmiedeberg's archives of pharmacology April 28, 2026 Yunsheng Liu, Rongde Zhong, Fenyong Yao et al.

Depression is a leading global health burden increasingly linked to dysregulation in glutamatergic signaling. Ionotropic glutamate receptors (iGluRs), including NMDA, AMPA, and kainate subtypes, have emerged as pivotal therapeutic targets. However, the rapid expansion of literature has led to a fragmented research landscape, creating an urgent need for a structured overview. This study aims to...

Ketamine-related neural changes in treatment-resistant depression: A multimodal synthesis of fMRI and PET studies.

Journal of Affective Disorders April 28, 2026 Nesreen Sedeek, Carley Rivers, Lucas Williamson et al.

Ketamine produces rapid antidepressant effects in a subset of patients with treatment-resistant depression, yet neuroimaging findings have been difficult to integrate because studies differ in imaging modality, analytic approach, task context, and post-infusion timing. To address this, we conducted a multimodal synthesis of functional magnetic resonance imaging (fMRI) and positron emission...

Baseline EEG Temporal Dynamics as a Thalamic Filter State Biomarker: A Thalamic Filter Model Account of Ketamine Antidepressant Response Prediction and Depression as Thalamic Over-Filtering

Zenodo (CERN European Organization for Nuclear Research) April 27, 2026 Ryan Malone

Treatment-resistant depression (TRD) affects approximately 30% of major depressive disorder(MDD) cases and represents a major unmet clinical need. Ketamine produces rapid antidepressanteffects in TRD, but response is variable and no validated biomarker predicts who will respond.Multiple independent studies have now shown that baseline EEG features -- particularly vigilancestage distribution and...

DOI: 10.5281/zenodo.19818580 (opens in new tab) Ketamine Baseline sea Electroencephalography Filter signal processing +2

Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series.

BMC Psychiatry April 26, 2026 Sergi López-rodríguez, Cinto Segalàs, Eva Real et al.

BACKGROUND: Patients with obsessive–compulsive disorder (OCD) and comorbid major depressive disorder (MDD) represent a severe subgroup with increased treatment resistance, greater functional impairment, and limited therapeutic options. Intranasal esketamine is a rapidly acting treatment for resistant depression, with emerging interest in potential anti-obsessional effects. However, prospective...

DOI: 10.1186/s12888-026-08119-5 (opens in new tab) Full text (opens in new tab) Major depressive disorder Comorbidity Intranasal esketamine Obsessive–compulsive disorder +2

Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression.

Journal of psychopharmacology (Oxford, England) April 24, 2026 Marco Colizzi, Elisa Morandin, Veronica Croccia et al.

Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...

The Monoamine-Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry.

Pharmaceuticals (Basel, Switzerland) April 24, 2026 Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli et al.

Background/Objectives: Major depressive disorder (MDD) remains a leading cause of disability worldwide and exhibits substantial biological heterogeneity that is not adequately captured by current symptom-based diagnostic systems. While the classical monoamine hypothesis has historically guided antidepressant development, it does not fully account for variability in treatment response, delayed...

Neuroscientific Basis of Ketamine as an Analgesic and Emerging Role in the Management of Depression.

Current Pain and Headache Reports April 21, 2026 Navy C Coggins, Hanson A Chokr, Tricia A Meyer et al.

PURPOSE OF REVIEW: Ketamine was originally developed as a dissociative anesthetic and has remained a valuable agent in anesthesia related to its ability to preserve airway reflexes and relative hemodynamic stability. Over time, its clinical applications have expanded beyond procedural sedation to include roles in pain management and psychiatry. In pain medicine, the therapeutic rationale is...

Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial.

Scientific Reports April 21, 2026 Rong Ding, Daojie Wang, Guoxin Wang et al.

Elderly colorectal cancer (CRC) patients face high risks of postoperative depression state, inadequately addressed by opioid-based analgesia. Esketamine, an NMDA receptor antagonist with rapid antidepressant effects, offers potential benefits but lacks evidence in this population. This double-blind RCT enrolled 99 elderly (≥ 65 years) CRC resection patients, randomized to three postoperative...

DOI: 10.1038/s41598-026-49287-4 (opens in new tab) Full text (opens in new tab) Esketamine Colorectal cancer Elderly Patient-controlled analgesia +1

Protocol and pilot results for a double-blind randomized placebo-controlled trial of ketamine under propofol sedation for chronic pain and depression.

Pain Management April 16, 2026 Theresa R. Lii, Pilleriin Sikka, Ben Deverett et al.

INTRODUCTION Ketamine shows promise for treatment-refractory chronic pain and depression, but randomized trials risk unblinding from ketamine's acute dissociative effects. Propofol sedation may mitigate this, though it has not been prospectively tested as a masking strategy outside of surgical contexts. METHODS This protocol describes a single-center, randomized, double-blind,...

Comparison of average time-to-relapse following ECT versus ketamine - A systematic review.

Journal of psychopharmacology (Oxford, England) April 16, 2026 Minna Chang, Allan H. Young, Mario F Juruena

Previous systematic reviews and meta-analyses have reported impressive antidepressant effects of ketamine in treatment-resistant depression (TRD). While ketamine has been compared with electroconvulsive therapy (ECT), the gold standard treatment, the extent and durability of its antidepressant effects over longer periods remain unclear. To our knowledge, this is the first systematic review...